City Therapeutics IPO: RNAi Stock Debuts on Nasdaq
City Therapeutics (NASDAQ: CTY) IPO: RNAi Biotechnology Stock Makes Its Market Debut City Therapeutics (NASDAQ: CTY) priced its initial public offering at $18.00 per share, raising approximately $200.00 million in gross proceeds. The clinical-stage biotechnology company develops RNA interference…